Cemiplimab Combo Does Not Show Superior ORR to Anti-PD-1 Monotherapy in Advanced HNSCC

Treatment for patients with HNSCC has evolved with the introduction of immunotherapy. For example, anti—PD-1 agents pembrolizumab (Keytruda) and nivolumab (Opdivo) have received FDA approval for the treatment of patients who have progressed on platinum-based chemotherapy, with response rates of 18% and 13%, respectively. However, additional treatment options for this patient population are needed.

In an open-label, multicenter, ascending dose-escalation phase I trial (NCT02383212), investigators are evaluating the use of cemiplimab alone and in combination with other anticancer therapies in patients with advanced malignancies.

For the phase I expansion cohort of patients with recurrent or metastatic HNSCC, investigators aimed to evaluate the efficacy, safety, tolerability, and dose-limiting toxicities of the cemiplimab combination regimen.

A total of 15 patients with recurrent/metastatic HNSCC who were refractory to first-line therapy and had disease for which palliative radiotherapy was clinically indicated were enrolled in the phase I expansion cohort. The subsites of the head and neck tumors were as follows: oral cavity in 6 patients (40.0%), hypopharynx in 3 (20.0%), oropharynx in 3 (20.0%), larynx in 2 (13.3%), and oropharyngeal in 1 (6.7%).

Patients were eligible to enroll if they were 18 years or older, had an ECOG performance status of 0 or 1, had acceptable organ function, and had at least 1 lesion determined to be measurable via RECIST v1.1 criteria.

Those who had ongoing or recent autoimmune disease and received systemic immunosuppressive treatment, received prior treatment with a PD-1/PD-L1 inhibitor, had brain metastases that had not been treated or could be considered active, had pneumonitis within the past 5 years, received immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within 4 weeks of beginning cemiplimab, or had a known hypersensitivity to GM-CSF or any component that contains yeast-derived products were ineligible for enrollment.

Patients received 3 mg/kg of cemiplimab intravenously (IV) once biweekly for up to 48 weeks (up to 6 cycles, with each cycle consisting of 56 days), plus daily 250 μg of GM-CSF in the first 7 days of a 2-week cycle for a total of 4 cycles, plus 27 gray (Gy) of radiotherapy—9 Gy 3 times over 1 week—starting 1 week after the first dose of cemiplimab, in addition to 300 mg/m²of IV cyclophosphamide every 14 days for a total of 4 doses. Investigators also performed response assessments every 8 weeks to measure ORR.

At the September 1, 2017, cut-off date, 3 patients (20.0%) were still on treatment, while the majority of patients (n = 12; 80.0%) had discontinued treatment, mostly due to disease progression (n = 8). The median number of doses of cemiplimab administered was 6 (range, 1-19), while the median duration of exposure to the drug was 12.3 weeks (range, 2.0-41.7) and the median duration of follow-up was 3.3 months (range, 0.5-10.2).

Results showed that the median progression-free survival in those who received the cemiplimab combination was 1.8 months (95% CI, 1.7-4.7), while the overall tumor response rate was 6.7% (95% CI, 0.2%-3.19%). One patient experienced a partial response (6.7%), 5 had stable disease (33.3%), 7 had progressive disease (46.7%), and 2 were not evaluable (13.3%).

The safety profile of the cemiplimab combination proved consistent with safety profiles that had been previously reported with cemiplimab monotherapy. No new safety signals were reported.

All-grade treatment-emergent adverse events (TEAEs) were observed in 14 of the 15 patients (93.3%). The most common TEAEs, regardless of attribution, included fatigue (n = 6), constipation (n = 4), asthenia (n = 3), dyspnea (n = 3), maculo-papular rash (n = 3), pneumonia (n = 3), arthralgia (n = 2), decreased appetite (n = 2), dehydration (n = 2), hypokalemia (n = 2), nausea (n = 2), rash (n = 2), stomatitis (n = 2), and weight decrease (n = 2).

Six patients (40.0%) experienced serious TEAEs, and the most frequent grade ≥3 TEAE was pneumonia (n = 2; 13.3%). One TEAE, community-acquired pneumonia, resulted in treatment discontinuation (6.7%).

The investigators concluded that the use of cemiplimab in combination with radiotherapy, cyclophosphamide, and GM-CSF did not show greater efficacy than what has been achieved with other PD-1 inhibitor monotherapies in patients with recurrent or metastatic HNSCC.

Reference:

Babiker HM, Brana I, Mahadevan D, et al. Phase 1 expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).Ann Oncol. 2018;29(suppl):8. Abstract 1171P. doi: 10.1093/annonc/mdy288.044.